Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

June 18, 2024

https://www.globenewswire.com/news-release/2024/06/18/2900393/0/en/Intelligent-Bio-Solutions-Begins-Subject-Dosing-and-Sampling-for-FDA-510-k-Pharmacokinetic-PK-Study-for-its-Intelligent-Fingerprinting-Drug-Screening-Technology.html

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq:INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is entering the next phase of its planned 510(k) submission to the FDA. The Company has successfully completed subject screening for its Pharmacokinetic (PK) Study and will begin dosing and sampling study subjects today.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.